Hunter Associates Investment Management LLC maintained its stake in Eli Lilly and Company (NYSE:LLY) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,903 shares of the company’s stock at the close of the second quarter. Hunter Associates Investment Management LLC’s holdings in Eli Lilly and were worth $897,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Acrospire Investment Management LLC increased its stake in shares of Eli Lilly and by 16.7% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares in the last quarter. Point72 Asia Hong Kong Ltd increased its stake in shares of Eli Lilly and by 237.4% during the 1st quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock worth $148,000 after purchasing an additional 1,239 shares in the last quarter. Shine Investment Advisory Services Inc. purchased a new position in shares of Eli Lilly and during the 2nd quarter worth approximately $148,000. Cornerstone Advisors Inc. increased its stake in shares of Eli Lilly and by 18.4% during the 2nd quarter. Cornerstone Advisors Inc. now owns 2,013 shares of the company’s stock worth $166,000 after purchasing an additional 313 shares in the last quarter. Finally, Penserra Capital Management LLC increased its stake in shares of Eli Lilly and by 9.5% during the 1st quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock worth $170,000 after purchasing an additional 176 shares in the last quarter. 75.48% of the stock is owned by institutional investors.

A number of brokerages have recently weighed in on LLY. BMO Capital Markets set a $73.00 price objective on shares of Eli Lilly and and gave the stock a “sell” rating in a research note on Tuesday, October 24th. Barclays PLC raised their price objective on shares of Eli Lilly and from $90.00 to $98.00 and gave the stock an “overweight” rating in a research note on Friday, October 13th. Berenberg Bank reissued a “buy” rating and set a $98.00 price objective on shares of Eli Lilly and in a research note on Thursday, October 26th. Zacks Investment Research cut shares of Eli Lilly and from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. Finally, Cowen and Company reissued a “buy” rating and set a $95.00 price objective on shares of Eli Lilly and in a research note on Wednesday, October 4th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $89.76.

In related news, SVP Alfonso G. Zulueta sold 2,003 shares of Eli Lilly and stock in a transaction on Friday, November 10th. The shares were sold at an average price of $83.67, for a total transaction of $167,591.01. Following the transaction, the senior vice president now owns 43,580 shares in the company, valued at approximately $3,646,338.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 205,000 shares of Eli Lilly and stock in a transaction on Wednesday, October 4th. The shares were sold at an average price of $86.81, for a total transaction of $17,796,050.00. The disclosure for this sale can be found here. Insiders have sold a total of 772,003 shares of company stock worth $64,837,441 in the last 90 days. Company insiders own 0.20% of the company’s stock.

WARNING: This piece was posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.watchlistnews.com/eli-lilly-and-company-lly-position-held-by-hunter-associates-investment-management-llc/1704054.html.

Eli Lilly and Company (NYSE LLY) opened at $82.49 on Wednesday. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66. The firm has a market cap of $91,236.74, a price-to-earnings ratio of 20.26, a price-to-earnings-growth ratio of 1.83 and a beta of 0.34. Eli Lilly and Company has a 1-year low of $64.18 and a 1-year high of $89.09.

Eli Lilly and (NYSE:LLY) last posted its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.03 by $0.02. The business had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The business’s quarterly revenue was up 9.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.88 EPS. equities research analysts expect that Eli Lilly and Company will post 4.22 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Wednesday, November 15th will be issued a dividend of $0.52 per share. The ex-dividend date of this dividend is Tuesday, November 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.52%. Eli Lilly and’s payout ratio is 98.58%.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.